The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 5, 2014, Pages 983-990

  Hong, Xin ^b   O'Donnell, James P ^b   Salazar, Clarence R ^b   Van Brocklyn, James R ^a   Barnett, Kahlil D ^a   Pearl, Dennis K ^a   DeCarvalho, Ana C ^b   Ecsedy, Jeffrey A ^c   Brown, Stephen L ^b   Mikkelsen, Tom ^b   Lehman, Norman L ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Alisertib; Aurora A; Glioblastoma; MLN8237; Neurospheres; Radiation; Temozolomide

Indexed keywords

ALISERTIB; AURORA A KINASE; PHOSPHOTHREONINE; TEMOZOLOMIDE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ASTROCYTE; CANCER STEM CELL; CELL ASSAY; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; ENZYME INHIBITION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IONIZING RADIATION; MTT ASSAY; NEUROSPHERE STEM CELL; PRIORITY JOURNAL; SOFT AGAR COLONY FORMATION ASSAY; WESTERN BLOTTING;

APOPTOSIS; AZEPINES; CELL PROLIFERATION; DACARBAZINE; GLIOBLASTOMA; HUMANS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RADIATION, IONIZING;

EID: 84900789677     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2430-z     Document Type: Article

References (24)

1. ClinicalTrials.gov, a service of the U.S. National Institutes of Health. www.clinicaltrials.gov. Accessed 12 Oct 2013
2. Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST, Giles FJ, Carew JS (2011) The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukemia and significantly increases the efficacy of nilotinib. J Cell Mol Med 15:2057-2070
3. Görgün G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, Santo L, Tai YT, Nahar S, Zheng M, Bandi M, Carrasco RD, Raje N, Munshi N, Richardson P, Anderson KC (2010) A novel aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell cycle arrest in multiple myeloma. Blood 115:5202-5213
4. Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, Stroud SG, Chen W, Shinde V, Huck JJ, Wysong DR, Janowick DA, Hyer ML, Leroy PJ, Gershman RE, Silva MD, Germanos MS, Bolen JB, Claiborne CF, Sells TB (2011) Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 17:7614-7624
5. Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatakrishnan K, Manfredi M, Fingert H, Burris HA 3rd, Infante JR (2012) Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 18:4775-4784
6. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S (1998) Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20:189-193 (Pubitemid 28455454)
7. Marumoto T, Honda S, Hara T, Nitta M, Hirota T, Kohmura E, Saya H (2003) Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 278: 51786-51795 (Pubitemid 38020425)
8. Seki A, Coppinger JA, Jang CY, Yates JR, Fang G (2008) Bora and the kinase Aurora A cooperatively activate the kinase Plk1 and control mitotic entry. Science 320:1655-1658 (Pubitemid 351931258)
9. Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, Gorlick R, Kolb EA, Keir ST, Wu J, Wozniak AE, Yang Y, Manfredi M, Ecsedy J, Wang J, Neale G, Houghton PJ, Smith MA, Lock RB (2011) Efficacy and pharmacokinetic/ pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol 68:1291-1304
10. Huck JJ, Zhang M, McDonald A, Bowman D, Hoar KM, Stringer B, Ecsedy J, Manfredi MG, Hyer ML (2010) MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res 8:373-384
11. Otto T, Horn S, Brockmann M, Eilers U, Schüttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R, Christiansen H, Berwanger B, Eilers M (2009) Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15:67-78
12. Yang S, He S, Zhou X, Liu M, Zhu H, Wang Y, Zhang W, Yan S, Quan L, Bai J, Xu N (2010) Suppression of Aurora-A oncogenic potential by c-Myc downregulation. Exp Mol Med 42:759-767
13. Sasayama T, Marumoto T, Kunitoku N, Zhang D, Tamaki N, Kohmura E, Saya H, Hirota T (2005) Over-expression of Aurora-A targets cytoplasmic polyadenylation element binding protein and promotes mRNA polyadenylation of Cdk1 and Cyclin B1. Genes Cells 10:627-638 (Pubitemid 40932344)
14. Lehman NL, O'Donnell JP, Whiteley LJ, Stapp RT, Lehman TD, Roszka KM, Schultz LR, Williams CJ, Mikkelsen T, Brown SL, Ecsedy JA, Poisson LM (2010) Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas. Cell Cycle 11:489-502
15. deCarvalho AC, Nelson K, Lemke N, Lehman NL, Arbab AS, Kalkanis S, Mikkelsen T (2010) Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo. Stem Cells 28:181-190
16. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, Black KL, Yu JS (2004) Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23:9392-9400 (Pubitemid 40069671)
17. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64:7011-7021 (Pubitemid 39331011)
18. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK, Fine HA (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9:391-403 (Pubitemid 43668737)
19. Lim SK, Gopalan G (2007) Aurora-A kinase interacting protein 1 (AURKAIP1) promotes Aurora-A degradation through an alternative ubiquitin-independent pathway. Biochem J 403:119-127 (Pubitemid 46569873)
20. Fumoto K, Lee PC, Saya H, Kikuchi A (2008) AIP regulates stability of Aurora-A at early mitotic phase coordinately with GSK-3beta. Oncogene 27:4478-4487
21. Qin L, Tong T, Song Y, Xue L, Fan F, Zhang G (2009) Aurora-A interacts with Cyclin B1 and enhances its stability. Cancer Lett 275:77-85
22. Asteriti IA, Rensen WM, Lindon C, Lavia P, Guarguaglini G (2010) The Aurora-A/TPX2 complex: a novel oncogenic holoenzyme? Biochim Biophys Acta 1806:230-239
23. Borges KS, Castro-Gamero AM, Moreno DA, da Silva Silveira V, Brassesco MS, de Paula Queiroz RG, de Oliveira HF, Carlotti CG Jr, Scrideli CA, Tone LG (2012) Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells. J Cancer Res Clin Oncol 138:405-414
24. Venkataraman S, Alimova I, Tello T, Harris PS, Knipstein JA, Donson AM, Foreman NK, Liu AK, Vibhakar R (2012) Targeting Aurora kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells. J Neurooncol 107:517-526